Résumé
Objective: This study was initiated to assess procalcitoninas prognostic marker forcardiovascular complication in type2 diabetic patients
Subjects and methods: Forty type 2 diabetic patients without cardiovascular disease, forty type 2 diabetic patients with cardiovascular disease and twenty healthy control counterparts were included in the present study. Serum procalcitoninlevels were assayed and correlated with metabolic parameters.ROC curve analysis was also done for this biochemical marker
Results: The mean level of procalcitonin was 707.17+/- 99.19ng/l in diabetic subjects versus 881.30+/- 123.56ng/l for the cardio-diabetic subjects [P < 0.0001]. Procalcitonin levels were significantly amplified in the cardio-diabetic patients with increasing C-reactive protein [CRP], triglycerides [TG], fasting blood glucose [FBG],and cholesterol [P = 0.004, 0.0005, 0.002 and 0.01 respectively]. From ROC curve analysis, it was observed that the area under curve for procalcitoninwas 0.878. This finding indicates the good validity of the above biomarker as aprognostic factor for cardiovascular complication in type 2 diabetic patients
Conclusion: This study evidences the usefulness of measuring serum levels of procalcitoninin diagnosis of cardiovascular complication in type 2 diabetic patients
Résumé
Objective: The present study was aimed to assess chemerin as prognostic factor for cardiovascular complications in type2 diabetic patients
Patients and methods: Forty type 2 diabetic patients without cardiovascular disease, forty type 2 diabetic patients with cardiovascular disease and twenty healthy control counterparts were included in the present study. Chemerin levels were assayed and correlated with clinical pathological parameters. ROC curve analysis was also done for this biochemical marker
Results: The mean level of chemerin was 57.65+/- 15.69 ng/l in diabetic subjects versus 93.97 +/- 26.62 ng/l for the cardio-diabetic subjects [P < 0.0001].The chemerin levels were significantly elevated in the cardio-diabetic patients with increasing-reactive protein[CRP], triglycerides[TG], fasting blood glucose [FBG], glycated hemoglbin[HbA1C], micro-albumin and cholesterol [P < 0.0001, P < 0.0001, P = 0.005, P=0.04, P=0.011andP=0.0001 respectively]. From the ROC curve analysis, it was observed that the area under curve for chemerin was 0.877. This finding indicates the good validity of the above biomarker as a prognostic factor for cardiovascular complication in type 2 diabetic patients
Conclusion: It could be concluded that chemerin can be used as prognostic biomarker for cardiovascular complications in type 2 diabetic patients
Résumé
Type 2 Diabetes is the common form of diabetes accounting for 90% of diabetic cases. As the incidence of type 2 diabetes is increasing the development of diabetic nephropathy. Nephropathy is one of the serious long-term complications of diabetes and may develop in 30-40% of diabetes mellitus patients. Endothelial inflammation has been implicated in the development of diabetic nephropathy. Type 2 diabetic patients usually present endothelial dysfunction. Reduction of endothelial function in type 2 diabetic patients stimulates inflammation and increases the levels of circulating soluble adhesion molecules [Intercellular adhesion molecules [ICAM]]. Cell adhesion molecules are important in promoting the inflammatory response. The aim of the present study is to determine plasma concentration of ICAM-1 as a marker for endothelial activation among type 2 diabetic patients with or without nephropathy [as tool in early diagnosis of nephropathy as major diabetic complications] also to explore the relationship between plasma level of ICAM-1 and insulin resistance in the studied patients. This study includes 70 subjects; 50 patients with type 2 diabetes mellitus were divided into two groups; First group consisted of 20 type 2 diabetic patients without complications. The second group comprised 30 type 2 diabetic patients with nephropathy. The third group [healthy controls] includes 20 non-diabetic subjects without a family history of diabetes mellitus. The results show that the mean sICAM-1 level was significantly higher in the diabetic patients with nephropathy than in those without nephropathy and in the controls .Also insulin level increase in diabetic patients than control. In addition positive correlation between ICAM-1 and insulin resistance in studied subjects. It can be concluded that the association between ICAM-1 expression and insulin resistance found in this study is consistent with clinical evidence relating insulin resistance and inflammation and high levels of sICAM-1 suggest that sICAM-1 may play a role in the development of nephropathy in patients with type 2 diabetes mellitus and can be use as a marker for early diagnosis of nephropathy as a major diabetic complications